Biotech


  • beaker shelved
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How a scrapped Pfizer drug became a winner for SpringWorks

    SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

    By Alexandra Pecci • April 21, 2025
  • psilocybin lab
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A big moment is coming for psychedelics

    Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

    By April 18, 2025
  • tech clinical trial Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Tech for Clinical Trials

    Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

    By PharmaVoice staff
  • Downtown Raleigh, North Carolina, skyline with a sunset
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

    Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

    By Alexandra Pecci • April 16, 2025
  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    ‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?

    The biotech market is taking a beating amid Trump’s turbulent economic policies.

    By April 15, 2025
  • A person looks through a pipette while working at a laboratory bench.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip

    US risks losing biotech edge to China, report warns

    “There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

    By Ned Pagliarulo • April 9, 2025
  • Michelle Werner, Caffrey
    Image attribution tooltip
    Permission granted by Michelle Werner
    Image attribution tooltip
    Profile

    Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

    Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.

    By April 8, 2025
  • sperm pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A birth control pill for men makes moves in the clinic

    So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?

    By Kelly Bilodeau • April 7, 2025
  • robot hand pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The year’s biggest biotech haul shows investors are still chasing the AI dream

    Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.

    By April 4, 2025
  • HHS staff cuts
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Opinion

    Industry leaders react to HHS being ‘reduced to a shell’

    What healthcare watchdogs have said about the far-reaching job cuts this week.

    By Meagan Parrish and Amy Baxter • April 3, 2025
  • Mikael Dolsten, former CSO, Pfizer
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip
    Profile

    Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’

    Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.

    By April 1, 2025
  • megaphone quieted
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With government health info in limbo, drugmakers lose credible sources

    The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

    By Alexandra Pecci • April 1, 2025
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A recent gene therapy death shines a light on AAV safety

    This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

    By Kelly Bilodeau • March 31, 2025
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images
    Image attribution tooltip

    How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

    After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

    By March 27, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/PharmaVoice
    Image attribution tooltip

    Biogen plots new global headquarters in Kendall Square

    The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

    By Jacob Bell • March 25, 2025
  • biotech stealth
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotechs emerging from stealth take aim at pharma’s prime targets

    The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

    By Kelly Bilodeau • March 24, 2025
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

    The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

    By March 20, 2025
  • china biotech
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The key factors shaping China’s biopharma boom

    Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

    By Alexandra Pecci • March 19, 2025
  • Jay Hartenbach, COO, president, Diakanos Oncology
    Image attribution tooltip
    Permission granted by Diakanos
    Image attribution tooltip
    Q&A

    How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

    Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

    By March 18, 2025
  • radioactive syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

    Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

    By Kelly Bilodeau • March 17, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Q&A

    Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

    The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

    By March 17, 2025
  • The dome of the U.S. Capitol Building as seen at dawn.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

    Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

    By March 12, 2025
  • brain design with neuro points scattered
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

    Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

    By March 11, 2025
  • Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    What’s driving pharma’s layoffs in 2025

    Familiar foes in the industry have claimed a slew of jobs in recent months.

    By March 10, 2025
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The time is ripe for pharma M&A. Why are drugmakers holding out?

    The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

    By March 6, 2025
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    With patent losses on the horizon, Amgen refocuses its business strategy

    The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

    By Alexandra Pecci • March 5, 2025